Bionaturis has early-stage clinical programs underway, targeting diseases with unmet medical needs within specialty markets. The team is committed to build up a biopharmaceutical pipeline for veterinarian and human applications.
The company has a proven track record on consortia R&D initiatives for biomedical applications and it is always open to study new proposals from public and private research centres.
As result of these projects Bionaturis has successfully expressed complex proteins and antibody fragments, among others.
Outstanding on-going R&D initiatives:
TargetFish is a large collaborative project to be funded with 6 million euro by the European Commission 7th Framework programme. The project will run for 5 years starting autumn 2012. TargetFish, coordinated by Dr. Geert Wiegertjes (Department of Animal Sciences, Cell Biology & Immunology group) brings together leading European research groups that are experts on the fish immune system and enterprises from the Biotech and Veterinary sectors that aim to commercialize fish vaccines for European fish farming.
Watch Dr Ana de las Heras talking about the TARGETFISH project and the role of Bionaturis on it (watch video)
Cervipro Project is devoted to the development of a cost-effective and possibly oral vaccine against cervical cancer. This goal follows Bionaturis mission: providing fist-in-class drugs to a higher percentage of population.
Bionaturis Group takes part in this project, led by the German company BioEnergy GmbH & Consultant, along with the German Cancer Research Center.
The main task of Bionaturis in this project is the purification phase in its alternative platform.
Te company receives 184.847,40 Euros of funding from the Eurostars-2 Programme with co-funding from CDTI and the Research and Innovation Horizon 2020 Framework Programme from European Union.
Biomap project is devoted to the multivariate design of assays, with the ultimate goal of developing biomedicines using the pharmaceutical criteria for quality, security and efficacy designs (Quality by design or QbD).
The QbD method will be applied to the candidate selection processes for the development portfolio of each company in the consortium, reducing time and optimizing the process.
The Biomap consortium is led by Laboratories Rovi and includes Vaxdyn, Vivacell Biotechnology Spain, and Bionaturis.
To this project, Bionaturis will receive an incentive of 572.988€ granted by the CDTI from the Feder-Interconecta Programme, with the support of the Ministry of Economy and Competitiveness.
PREVENTION AND TREATMENT OF LEISHMANIASIS IN HUMANS
‘BNT005: Cellular immunity for the prevention and treatment of Leishmaniasis in humans. Research for the development of an innovative vaccine with high potential international market”, pursues to fulfill the non-regulatory preclinical assays, supported by the encouraging results obtained in Beagles dogs so far, in order to evaluate the human application of this vaccine. For this initiative Bionaturis shall partner up with the Lopez Neyra Institute – Spanish National Research Council (CSIC, in Spanish).
The company receives an incentive of 140.988,30 Euros during 2016 and 156.811,75 Euros as a loan, by the Spanish Ministry of Economy and Competitiveness – RETOS 2016 call cofounded by FEDER.
Development of a vaccine for treatment and prevention against canine visceral leishmaniasis.
It is founded by Ministry of Economy and Competitiveness, and co-founded by the FEDER Programme.
The Centre for Industrial and Technological Development (CDTI; Government of Spain) has granted BIOORGANIC RESEARCH AND SERVICES, S.A. with an incentive of 267,360.00 Euros to co-found its participation ) in the framework of the 2016 FEDER-Innterconecta Program with the reference ITC‐20161016 in the project titled ‘Vaccination Programmes based on the Chain of Infection for Reducing the Use of Antibiotics in Swine’, given to the consortium represented by PIENSOS JIMENEZ SL. This incentive has been co-founded by the
This incentive has been co-founded by the the Ministry of Economy, Industry and Competitiveness within the 2013-2016 National Plan of Scientific, Technical and Innovation Research; and by the European Union through the European Regional Development Fund (ERDF).